Blue Trust Inc. Has $125,000 Holdings in Myriad Genetics, Inc. (NASDAQ:MYGN)

Blue Trust Inc. cut its holdings in Myriad Genetics, Inc. (NASDAQ:MYGN) by 27.7% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 9,153 shares of the company’s stock after selling 3,510 shares during the period. Blue Trust Inc.’s holdings in Myriad Genetics were worth $125,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Nordea Investment Management AB increased its stake in Myriad Genetics by 117.0% in the 4th quarter. Nordea Investment Management AB now owns 332,913 shares of the company’s stock valued at $4,548,000 after buying an additional 179,527 shares during the last quarter. Jennison Associates LLC increased its position in shares of Myriad Genetics by 144.2% in the fourth quarter. Jennison Associates LLC now owns 59,015 shares of the company’s stock valued at $809,000 after acquiring an additional 34,853 shares during the last quarter. State of New Jersey Common Pension Fund D acquired a new position in shares of Myriad Genetics during the 3rd quarter worth approximately $1,965,000. Barclays PLC increased its position in shares of Myriad Genetics by 136.9% during the 3rd quarter. Barclays PLC now owns 190,243 shares of the company’s stock worth $5,210,000 after purchasing an additional 109,931 shares during the last quarter. Finally, Simplify Asset Management Inc. acquired a new position in shares of Myriad Genetics during the 3rd quarter worth approximately $4,756,000. 99.02% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. UBS Group initiated coverage on shares of Myriad Genetics in a report on Tuesday, December 10th. They set a “neutral” rating and a $18.00 target price on the stock. StockNews.com cut Myriad Genetics from a “buy” rating to a “hold” rating in a report on Thursday. Stephens reaffirmed an “equal weight” rating and issued a $20.00 price objective on shares of Myriad Genetics in a research report on Thursday, January 16th. Leerink Partners lowered Myriad Genetics from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $30.00 to $21.00 in a report on Monday, December 9th. Finally, Piper Sandler cut their price target on Myriad Genetics from $24.00 to $14.00 and set a “neutral” rating for the company in a report on Thursday, January 30th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $22.54.

Myriad Genetics Stock Performance

Shares of NASDAQ MYGN opened at $14.19 on Friday. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.90 and a quick ratio of 1.73. The stock’s fifty day moving average price is $13.45 and its two-hundred day moving average price is $19.57. Myriad Genetics, Inc. has a one year low of $12.04 and a one year high of $29.30. The firm has a market cap of $1.29 billion, a price-to-earnings ratio of -10.92 and a beta of 1.88.

About Myriad Genetics

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.